LINCOLN.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 10:48):

Stats
Šios dienos apimtis	12 913.00
Vidutinė apimtis	101 918
Rinkos kapitalizacija	12.01B
EPS	INR0 ( 2024-02-08 )
Kita pelno data	( INR0 ) 2024-05-22
Last Dividend	INR1.500 ( 2023-09-15 )
Next Dividend	INR0 ( N/A )
P/E	13.76
ATR14	INR0.793 (0.13%)

Tūris Koreliacija

Ilgas: 0.13 (neutral)

Trumpas: 0.51 (weak)

Signal:(53.838) Neutral

Lincoln Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lincoln Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.05
( neutral )

-0.36
( neutral )

0.36
( neutral )

-0.31
( neutral )

-0.09
( neutral )

-0.16
( neutral )

Lincoln Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	INR5.10B
Bruto pelnas:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Pajamos:	INR5.10B
Bruto pelnas:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Pajamos:	INR4.68B
Bruto pelnas:	INR2.48B (53.06 %)
EPS:	INR34.63

FY	2021
Pajamos:	INR4.15B
Bruto pelnas:	INR2.16B (52.05 %)
EPS:	INR31.11

Financial Reports:

No articles found.

Lincoln Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lincoln Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.60 - low (52.89%) | Divividend Growth Potential Score: 5.27 - Stable (5.42%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.000	2016-09-23
Last Dividend	INR1.500	2023-09-15
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR11.20	--
Avg. Dividend % Per Year	0.32%	--
Score	2.19	--
Div. Sustainability Score	4.60
Div.Growth Potential Score	5.27
Div. Directional Score	4.94	--

Next Divdend (Est)
(2024-06-25)

INR1.526 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.19

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.500	0.67%
2019	INR1.500	0.66%
2020	INR1.500	0.73%
2021	INR1.500	0.62%
2022	INR1.500	0.41%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RPPL.NS	Dividend Junior	2023-08-24	Annually	6	0.31%
LIKHITHA.NS	Dividend Junior	2023-09-20	Annually	4	0.46%
GANESHHOUC.NS	Dividend Junior	2023-08-31	Sporadic	18	0.18%
APTUS.NS	Dividend Junior	2023-05-12	Semi-Annually	3	0.32%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
ONGC.NS	Dividend Knight	2023-08-18	Semi-Annually	28	4.00%
IOC.NS	Dividend Knight	2023-07-28	Semi-Annually	28	5.08%
CRAFTSMAN.NS	Dividend Knight	2023-06-19	Annually	3	0.13%
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANGCHEFER.NS	Dividend Junior	2023-09-18	Annually	17	1.18%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.159	1.500	6.83	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	47.50	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.34	2.00	4.83	9.66	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.487	1.000	5.22	5.22	[0.2 - 0.8]
operatingProfitMarginTTM	0.182	1.000	8.35	8.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.60

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.66	1.000	8.72	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.34	2.00	6.55	9.66	[0 - 30]
dividendYielPercentageTTM	0.252	1.500	3.70	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0376	1.000	-1.560	0	[0.1 - 0.5]
Total Score				5.27

Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.